High Growth Tech Stocks In Sweden To Watch This September 2024

As global markets react to robust stimulus measures from China and mixed economic signals from the U.S., Sweden's tech sector remains a focal point for investors seeking high-growth opportunities. With major indices like the S&P 500 reaching record highs, it's crucial to identify stocks that can leverage current market dynamics, such as technological advancements and favorable economic policies. A good stock in this environment typically exhibits strong innovation potential, solid financial health, and the ability to adapt quickly to changing market conditions.

Top 10 High Growth Tech Companies In Sweden

Name	Revenue Growth	Earnings Growth	Growth Rating
Truecaller	20.32%	21.61%	★★★★★★
Fortnox	20.04%	22.24%	★★★★★★
Bonesupport Holding	33.76%	31.20%	★★★★★★
Xbrane Biopharma	53.90%	118.02%	★★★★★★
Scandion Oncology	40.71%	75.34%	★★★★★★
Hemnet Group	20.13%	25.41%	★★★★★★
Skolon	31.76%	121.72%	★★★★★★
BioArctic	42.38%	98.40%	★★★★★★
Yubico	20.52%	42.35%	★★★★★★
KebNi	34.75%	86.11%	★★★★★★

Click here to see the full list of 82 stocks from our Swedish High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Sectra (OM:SECT B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Sectra AB (publ) provides solutions for medical IT and cybersecurity sectors in Sweden, the United Kingdom, the Netherlands, and rest of Europe with a market cap of SEK53.56 billion.

Operations: Sectra AB (publ) generates revenue primarily from Imaging IT Solutions (SEK2.67 billion) and Secure Communications (SEK388.55 million), with additional contributions from Business Innovation (SEK90.77 million). The company operates in Sweden, the United Kingdom, the Netherlands, and across Europe.

Sectra, a Swedish tech firm, is demonstrating robust growth with its recent transition into cloud services, notably with the successful implementation of Sectra One Cloud in Belgium. This move underscores their strategic shift towards SaaS models, enhancing resource sharing and workflow efficiencies for healthcare providers. Financially, Sectra's revenue surged to SEK 739.48 million from SEK 603.03 million year-over-year as of July 2024, reflecting a significant uptick in earnings by 17%. Looking ahead, the company's revenue and earnings are expected to grow annually by 14.2% and 21.2%, respectively—outpacing the broader Swedish market projections of just 0.9% for revenue and 15.1% for earnings growth. This performance is anchored by substantial investments in R&D which not only fuel innovation but also solidify Sectra’s competitive edge in medical imaging technology—a sector where continuous advancement is critical for maintaining relevance and driving growth. These strategic initiatives could well position Sectra as a pivotal player in transforming healthcare technology through advanced software solutions that meet evolving global needs.

• Click here and access our complete health analysis report to understand the dynamics of Sectra.

• Explore historical data to track Sectra's performance over time in our Past section.

Swedish Orphan Biovitrum (OM:SOBI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company that researches, develops, manufactures, and sells pharmaceuticals in haematology, immunology, and specialty care across Europe, North America, the Middle East, Asia, and Australia with a market cap of SEK112.27 billion.

Operations: The company's revenue primarily comes from its pharmaceuticals in haematology (SEK15.07 billion), immunology (SEK7.49 billion), and specialty care (SEK1.15 billion). The focus on these therapeutic areas drives its financial performance across multiple regions, including Europe, North America, the Middle East, Asia, and Australia.

Swedish Orphan Biovitrum (Sobi), amidst a dynamic year, showcases its prowess in the biotech sector with significant strides in R&D and clinical advancements. The company's commitment to innovation is evident as R&D expenses surged by 25.9%, underscoring its dedication to addressing unmet medical needs through groundbreaking therapies like pegcetacoplan for rare kidney diseases. This focus on research not only enhances Sobi's product pipeline but also propels revenue growth, which is anticipated to outpace the Swedish market with a robust increase of 9.3% annually. Moreover, recent positive results from their Phase 3 studies highlight Sobi's potential to lead in niche markets, further solidifying its position within high-growth tech sectors in Sweden.

• Delve into the full analysis health report here for a deeper understanding of Swedish Orphan Biovitrum.

• Evaluate Swedish Orphan Biovitrum's historical performance by accessing our past performance report.

Yubico (OM:YUBICO)

Simply Wall St Growth Rating: ★★★★★★

Overview: Yubico AB provides authentication solutions for use in computers, networks, and online services, with a market cap of SEK21.79 billion.

Operations: Yubico AB generates revenue primarily from its Security Software & Services segment, amounting to SEK2.09 billion. The company focuses on providing authentication solutions for computers, networks, and online services.

Yubico, a Swedish tech firm, is making significant strides in the cybersecurity space with its innovative authentication solutions. The company's recent financial performance underscores robust growth, reporting a 36% increase in sales to SEK 1.11 billion for the first half of 2024, alongside an impressive net income rise to SEK 177.4 million from SEK 125.9 million year-over-year. With R&D expenses climbing by 20.5%, Yubico is heavily investing in developing advanced security technologies that cater to both enterprise and government needs, aligning with global shifts towards passwordless systems. This strategic focus not only enhances their product offerings but also positions them well within an increasingly security-conscious market where revenue and earnings are expected to grow by 20.5% and 42.3% annually.

• Unlock comprehensive insights into our analysis of Yubico stock in this health report.

• Gain insights into Yubico's past trends and performance with our Past report.

Make It Happen

• Embark on your investment journey to our 82 Swedish High Growth Tech and AI Stocks selection here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com